- Home
- LYEL vs NHS Comparison
LYEL vs NHS Comparison
Compare LYEL & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- NHS
- Stock Information
- Founded
- LYEL 2018
- NHS 2003
- Country
- LYEL United States
- NHS United States
- Employees
- LYEL N/A
- NHS N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- NHS Trusts Except Educational Religious and Charitable
- Sector
- LYEL Health Care
- NHS Finance
- Exchange
- LYEL Nasdaq
- NHS Nasdaq
- Market Cap
- LYEL 263.9M
- NHS 230.5M
- IPO Year
- LYEL 2021
- NHS N/A
- Fundamental
- Price
- LYEL $0.62
- NHS $7.54
- Analyst Decision
- LYEL Sell
- NHS
- Analyst Count
- LYEL 2
- NHS 0
- Target Price
- LYEL $1.00
- NHS N/A
- AVG Volume (30 Days)
- LYEL 1.5M
- NHS 111.8K
- Earning Date
- LYEL 11-07-2024
- NHS 01-01-0001
- Dividend Yield
- LYEL N/A
- NHS 13.44%
- EPS Growth
- LYEL N/A
- NHS N/A
- EPS
- LYEL N/A
- NHS N/A
- Revenue
- LYEL $63,000.00
- NHS N/A
- Revenue This Year
- LYEL N/A
- NHS N/A
- Revenue Next Year
- LYEL N/A
- NHS N/A
- P/E Ratio
- LYEL N/A
- NHS N/A
- Revenue Growth
- LYEL N/A
- NHS N/A
- 52 Week Low
- LYEL $0.58
- NHS $6.95
- 52 Week High
- LYEL $3.26
- NHS $9.17
- Technical
- Relative Strength Index (RSI)
- LYEL 27.76
- NHS 25.88
- Support Level
- LYEL $0.58
- NHS $7.74
- Resistance Level
- LYEL $0.95
- NHS $7.93
- Average True Range (ATR)
- LYEL 0.07
- NHS 0.06
- MACD
- LYEL -0.02
- NHS -0.02
- Stochastic Oscillator
- LYEL 6.48
- NHS 2.25
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.